Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ELEDON PHARMACEUTICALS INC
ELDN | US
3.20
USD-0.02
-0.62%
ELDN | US
About ELEDON PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
14/04/2026
Close
3.20
Open
3.25
High
3.31
Low
3.14
Eledon Pharmaceuticals Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart an anti-CD40L antibody with high affinity for CD40 Ligand a biological target with therapeutic potential. It has a collaboration agreement with eGenesis Inc. The company was formerly known as Novus Therapeutics Inc. and changed its name to Eledon Pharmaceuticals Inc. in January 2021. Eledon Pharmaceuticals Inc. is headquartered in Irvine California.
View LessELDN | US
Risk
73.0
Sharpe
0.09
Luna's Score
46/100
Recommendation
Hold
Luna says (ELDN | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
73.5%1 month
73.0%3 months
66.1%6 months
105.8%Returns
Fundamental Ratios
PE
6.60
Fwd. PE
5.39
Price to book
1.31
Debt to equity
-0.08
Debt to assets
0.01
Ent. to EBITDA
0.84
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-36.86M
MarketCap
132.43M
MarketCap(USD)
132.43M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-70.71
Short ratio
1.57
Short perc.
0.36
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.58
Range1M
0.66
Range3M
1.61
Volumes: Market Activity
Rel. volume
0.61
Price X volume
2.84M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.84 | - | Expensive |
| Ent. to Revenue | - | - | - |
| PE Ratio | 6.60 | 41.03 | Cheaper |
| Price to Book | 1.31 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 66.07 | - | Par |
| Debt to Equity | -0.08 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 132.43M | - | Emerging |
